edotreotide has been researched along with yttrium radioisotopes in 60 studies
| Studies (edotreotide) | Trials (edotreotide) | Recent Studies (post-2010) (edotreotide) | Studies (yttrium radioisotopes) | Trials (yttrium radioisotopes) | Recent Studies (post-2010) (yttrium radioisotopes) |
|---|---|---|---|---|---|
| 206 | 34 | 86 | 3,407 | 339 | 1,533 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (21.67) | 18.2507 |
| 2000's | 35 (58.33) | 29.6817 |
| 2010's | 11 (18.33) | 24.3611 |
| 2020's | 1 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bakker, WH; Béhé, M; Bernard, BF; Breeman, WA; de Jong, M; Jermann, E; Krenning, EP; Mäcke, HR; Powell, P; van der Pluijm, ME; Visser, TJ | 1 |
| Behe, M; Bucher, HC; Goetze, M; Heppeler, A; Jermann, E; Maecke, HR; Mueller-Brand, J; Otte, A; Roser, HW | 1 |
| Bakker, WH; Bernard, BF; Breeman, WA; de Jong, M; Krenning, EP; Mäcke, H; Rolleman, EJ; Visser, TJ | 1 |
| Dellas, S; Herrmann, R; Maecke, HR; Mueller-Brand, J; Nitzsche, EU; Otte, A | 1 |
| Albert, R; Bruns, C; Raulf, F; Smith-Jones, PM; Stolz, B; Weckbecker, G | 1 |
| Albert, R; Bruns, C; Knecht, H; Pless, J; Simeon, C; Smith-Jones, P; Stolz, B | 1 |
| Andreas, J; Bockisch, A; Brandt-Mainz, K; Bruns, C; Görges, R; Kahaly, G; Mäcke, H; Müller-Brand, J; Walgenbach, S | 1 |
| Brockmann, J; Herzog, H; Köhle, M; Marbach, P; Mühlensiepen, H; Müller-Gärtner, HW; Rösch, F; Stolz, B | 1 |
| Bakker, WH; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Mäcke, HR | 1 |
| Chinol, M; Cremonesi, M; Ferrari, M; Fiorenza, M; Jermann, E; Maecke, HR; Orsi, F; Paganelli, G; Robertson, C; Stabin, MG; Tosi, G; Zoboli, S | 1 |
| Herrmann, R; Mäcke, HR; Müller-Brand, J; Otte, A | 1 |
| Behe, M; Heppeler, A; Herrmann, R; Jermann, E; Maecke, HR; Muller, J; Otte, A; Powell, P | 1 |
| Chinol, M; Cremonesi, M; Mäcke, HR; Paganelli, G; Zoboli, S | 1 |
| Crazzolara, A; Haldemann, A; Maecke, HR; Mueller-Brand, J; Waldherr, C | 1 |
| Bakker, W; Chen, T; Jamar, F; Krenning, E; Kvols, L; Liu, J; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Yeh, CM | 1 |
| de Jong, M; Krenning, EP; Kwekkeboom, D | 1 |
| Brunner, FP; Maecke, HR; Mihatsch, MJ; Moll, S; Mueller-Brand, J; Nickeleit, V | 1 |
| Bartolomei, M; Chinol, M; Cremonesi, M; Ferrari, M; Fiorenza, M; Paganelli, G; Sacco, E; Stabin, MG; Tosi, G | 1 |
| Bartolomei, M; Bodei, L; Chinol, M; Cremonesi, M; de Braud, F; De Cicco, C; Ferrari, M; Grana, C; Mäcke, HR; Orsi, F; Paganelli, G; Zoboli, S | 1 |
| Bockisch, A; Görges, R; Kahaly, G; Mäcke, H; Müller-Brand, J; Roser, HW | 1 |
| Bartenstein, PR; Brockmann, JJ; Buchholz, HG; Engelbach, MJ; Förster, GJ; Herzog, HR; Mäcke, HR; Reber, HJ; Rösch, FR | 1 |
| Grossman, AB; Kaltsas, GA; Mukherjee, JJ | 1 |
| Eichhorn, K; Freitag, P; Gratzl, O; Hofer, S; Maecke, R; Merlo, A; Mueller-Brand, J; Probst, A; Reubi, JC; Schumacher, T; Wasner, M; Zimmerer, S | 1 |
| Cybulla, M; Otte, A; Weiner, SM | 3 |
| Arnold, R; Becker, W; Béhé, M; Behr, TM; Goldenberg, DM; Gotthardt, M; Gratz, S; Kluge, G; Schipper, ML | 1 |
| Bodei, L; Chinol, M; Cremonesi, M; Paganelli, G | 1 |
| Crazzolara, A; Haldemann, A; Maecke, HR; Mueller-Brand, J; Nitzsche, EU; Pless, M; Schumacher, T; Waldherr, C | 1 |
| de Jong, M; Krenning, E | 1 |
| Maecke, H; Mueller-Brand, J; Schumacher, T; Waldherr, C | 1 |
| Bartolomei, M; Bodei, L; Caracciolo, M; Chinol, M; Cremonesi, M; Grana, C; Mäcke, HR; Paganelli, G; Rocca, P; Zoboli, S | 1 |
| Barone, R; Bouterfa, H; Carlier, P; Chen, T; de Camps, J; Jamar, F; Krenning, EP; Kvols, LK; Labar, D; Mathieu, I; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Walrand, S | 1 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Karwal, M; Madsen, M; Menda, Y; O'Dorisio, T; Parker, S; Ponto, J; Ponto, L; Zehr, P | 1 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Karwal, M; Menda, Y; Miller, S; O'Dorisio, T; Parker, S; Zehr, P | 1 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Kahn, D; Karwal, M; Madsen, M; Menda, Y; Miller, S; O'Dorisio, S; O'Dorisio, T; Ponto, J; Squires, S; Walkner, W | 1 |
| Bartolomei, M; Bodei, L; Chinol, M; Cremonesi, M; Grana, C; Handkiewicz-Junak, D; Lopera Sierra, M; Mäcke, HR; Mazzetta, C; Paganelli, G; Rocca, P | 1 |
| Herrmann, R; Maecke, H; Meier, G; Mueller-Brand, J; Pless, M; Waldherr, C | 1 |
| Bartolomei, M; Bodei, L; Chinol, M; Cremonesi, M; Grana, C; Paganelli, G; Rocca, P | 1 |
| Arnold, R; Bartenstein, P; Bouterfa, H; Buchholz, HG; Förster, GJ; Göke, B; Haus, U; Helisch, A; Pauwels, S; Reber, H; Weber, MM; Wiedenmann, B | 1 |
| Bijster, M; De Jong, M; Konijnenberg, MW; Krenning, EP | 1 |
| Buitrago, C; Herrmann, R; Maecke, H; Mueller-Brand, J; Pless, M; Waldherr, C | 1 |
| Besse, IM; Bushnell, DL; Juweid, ME; Madsen, MT; Menda, Y; O'Dorisio, MS; O'Dorisio, T | 1 |
| Bockisch, A; Broelsch, CE; Frilling, A; Hofmann, M; Mueller-Brand, J; Saner, F; Weber, F | 1 |
| Causer, L; Chittenden, S; Flux, GD; Hindorf, C; Lewington, VJ; Mäcke, HR | 1 |
| Forrer, F; Maecke, HR; Mueller-Brand, J; Riedweg, I | 1 |
| Aricò, D; Baio, SM; Bartolomei, M; Bodei, L; Botteri, E; Cremonesi, M; De Cicco, C; Grana, CM; Paganelli, G; Sansovini, M | 1 |
| Arveschoug, AK; Hjorthaug, K; Højgaard, L; Mortensen, J; Oturai, PS; Rehling, M | 1 |
| Bodei, L; Paganelli, G; Pepe, G | 1 |
| Applebaum, L; Barak, D; Eckstein, J; Fraenkel, M; Gross, DJ; Grozinsky-Glasberg, S; Müeller-Brand, J; Shimon, I; Walter, MA | 1 |
| Baete, K; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C | 1 |
| Choyke, PL; Giesel, FL; Haberkorn, U; Haufe, S; Isermann, B; Kauczor, HU; Kratochwil, C; López-Benítez, R; Mier, W | 1 |
| Bertagna, F; Bettinsoli, G; Biasiotto, G; Bosio, G; Dognini, L; Ferrari, C; Ferrari, V; Franco, F; Giubbini, R; Migliorati, E; Minari, C; Rodella, C; Savelli, G; Tomassetti, P; Zaniboni, A | 1 |
| Briel, M; Brunner, P; Jörg, AC; Koller, MT; Maecke, HR; Marincek, N; Müller-Brand, J; Rochlitz, C; Schindler, C; Walter, MA | 1 |
| Bergsma, H; de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; Peeters, RP; Teunissen, JJ; van Vliet, EI | 1 |
| Cacciari, G; Campana, D; Capurso, G; Delle Fave, G; Falconi, M; Nori, F; Panzuto, F; Partelli, S; Tamburrino, D; Tomassetti, P | 1 |
| Baete, K; Bogaerts, K; Clement, PM; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C | 1 |
| Jeremic, MZ; Krstic, DZ; Matovic, MD; Nikezic, DR; Pantovic, SB | 1 |
| Bocci, V; Colandrea, M; Collamati, F; Cremonesi, M; Faccini, R; Ferrari, ME; Ferroli, P; Ghielmetti, F; Ghisini, R; Grana, CM; Mancini Terracciano, C; Marafini, M; Mirabelli, R; Morganti, S; Papi, S; Patanè, M; Pedroli, G; Pollo, B; Russomando, A; Schiariti, M; Solfaroli Camillocci, E; Traini, G | 1 |
| Baum, RP; Kulkarni, HR; Zhang, J | 1 |
5 review(s) available for edotreotide and yttrium radioisotopes
| Article | Year |
|---|---|
OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
Topics: Animals; Breast Neoplasms; Carcinoma, Small Cell; Dose-Response Relationship, Radiation; Female; Humans; Indium Radioisotopes; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasms; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes | 2000 |
Peptide receptor imaging and therapy.
Topics: Humans; Indium Radioisotopes; Neoplasms; Neuroendocrine Tumors; Octreotide; Oligopeptides; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2000 |
The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Yttrium Radioisotopes | 2001 |
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
Topics: Animals; Humans; Kidney Diseases; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
Topics: Antineoplastic Agents; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Somatostatin; Yttrium Radioisotopes | 2010 |
19 trial(s) available for edotreotide and yttrium radioisotopes
| Article | Year |
|---|---|
Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
Topics: Adult; Aged; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Yttrium Radioisotopes | 1999 |
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.
Topics: Adult; Aged; Female; Humans; Indicators and Reagents; Male; Middle Aged; Neoplasms; Octreotide; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tissue Distribution; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2001 |
Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glioma; Humans; Injections, Intralesional; Magnetic Resonance Imaging; Male; Middle Aged; Octreotide; Pilot Projects; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Receptors, Somatostatin; Sensitivity and Specificity; Treatment Outcome; World Health Organization; Yttrium Radioisotopes | 2002 |
Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasms; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes | 2002 |
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
Topics: Adult; Aged; Amino Acids; Biomarkers, Tumor; Blood Platelets; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hemoglobins; Humans; Kidney; Lymphocytes; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Octreotide; Radiation-Protective Agents; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Renal Insufficiency; Vomiting; Yttrium Radioisotopes | 2003 |
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes | 2003 |
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.
Topics: Alanine Transaminase; Alkaline Phosphatase; Analysis of Variance; Aspartate Aminotransferases; Carcinoma, Neuroendocrine; Clinical Protocols; Disease Progression; Humans; Liver; Liver Neoplasms; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2003 |
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.
Topics: Adult; Aged; Dose-Response Relationship, Radiation; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Quality of Life; Radiography; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Topics: Body Burden; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Injuries; Radiation Protection; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Relative Biological Effectiveness; Risk Assessment; Risk Factors; Somatostatin; Tissue Distribution; Yttrium Radioisotopes | 2004 |
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
Topics: Aged; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2006 |
Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors.
Topics: Adult; Aged; Dose-Response Relationship, Radiation; Female; Humans; Kidney; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiometry; Yttrium Radioisotopes | 2007 |
Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
Topics: Adult; Female; Humans; Lutetium; Male; Middle Aged; Neoplasm Staging; Octreotide; Paraganglioma; Pheochromocytoma; Staining and Labeling; Yttrium Radioisotopes | 2008 |
Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Young Adult; Yttrium Radioisotopes | 2009 |
Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
Topics: Adult; Aged; Chromogranin A; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |
Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Radionuclide Imaging; Retreatment; Survival Rate; Yttrium Radioisotopes | 2012 |
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Radiation; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiotherapy; Somatostatin; Young Adult; Yttrium Radioisotopes | 2013 |
Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
Topics: Adult; Aged; Digestive System Neoplasms; Female; Humans; Kidney; Kidney Function Tests; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Precision Medicine; Radiation Dosage; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes | 2014 |
36 other study(ies) available for edotreotide and yttrium radioisotopes
| Article | Year |
|---|---|
Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
Topics: Animals; Indium Radioisotopes; Male; Octreotide; Pentetic Acid; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Rats, Wistar; Receptors, Somatostatin; Tissue Distribution; Yttrium Radioisotopes | 1997 |
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
Topics: Abdominal Neoplasms; Adult; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Sensitivity and Specificity; Yttrium Radioisotopes | 1997 |
D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Topics: Animals; Indium Radioisotopes; Kidney; Lysine; Male; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution; Yttrium Radioisotopes | 1997 |
Yttrium-90-labelled somatostatin-analogue for cancer treatment.
Topics: Adult; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes | 1998 |
The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.
Topics: Animals; Humans; Octreotide; Pancreatic Neoplasms; Polymerase Chain Reaction; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Tissue Distribution; Yttrium Radioisotopes | 1998 |
Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man.
Topics: Drug Carriers; Heterocyclic Compounds, 1-Ring; Humans; Indicators and Reagents; Iodine Radioisotopes; Neoplasms; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes | 1998 |
[Somatostatin receptor status in non-medullary thyroid carcinoma].
Topics: Adenocarcinoma, Follicular; Adult; Aged; Autoradiography; Carcinoma, Papillary; Female; Humans; Indium Radioisotopes; Iodine Radioisotopes; Male; Middle Aged; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Thyroid Neoplasms; Tomography, Emission-Computed; Yttrium Radioisotopes | 1999 |
Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue.
Topics: Anesthesia; Animals; Female; Image Processing, Computer-Assisted; Ligands; Male; Octreotide; Papio; Quality Control; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed; Yttrium Radioisotopes | 1999 |
Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Topics: Adult; Aged; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tissue Distribution; Yttrium Radioisotopes | 1999 |
Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.
Topics: Adult; Aged; Humans; Indium Radioisotopes; Middle Aged; Octreotide; Radiation Dosage; Radiopharmaceuticals; Receptors, Somatostatin; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 1999 |
[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
Topics: Female; Follow-Up Studies; Humans; Middle Aged; Neuroendocrine Tumors; Octreotide; Pilot Projects; Prospective Studies; Radiation Injuries; Radionuclide Imaging; Radiotherapy Dosage; Receptors, Somatostatin; Treatment Outcome; Yttrium Radioisotopes | 1999 |
Yttrium-90 DOTATOC: first clinical results.
Topics: Adult; Aged; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neoplasms; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes | 1999 |
Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
Topics: Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Paraplegia; Radiopharmaceuticals; Somatostatin; Spinal Cord Compression; Spinal Neoplasms; Thoracic Vertebrae; Yttrium Radioisotopes | 2000 |
A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy.
Topics: Biopsy; Carcinoma, Neuroendocrine; Female; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Octreotide; Radiation Injuries; Thrombosis; Yttrium Radioisotopes | 2001 |
Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
Topics: Humans; Indium Radioisotopes; Neoplasms; Octreotide; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2000 |
Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes | 2001 |
Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Topics: Aged; Carcinoid Tumor; Humans; Indium Radioisotopes; Male; Middle Aged; Octreotide; Radiation Dosage; Radiometry; Radiopharmaceuticals; Somatostatin; Tissue Distribution; Tomography, Emission-Computed; Yttrium Radioisotopes | 2001 |
Is radiation nephropathy caused by yttrium-90?
Topics: Dose-Response Relationship, Drug; Humans; Kidney; Octreotide; Radioimmunotherapy; Yttrium Radioisotopes | 2002 |
Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis.
Topics: Animals; Humans; Kidney; Neoplasms; Octreotide; Peptides; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2002 |
Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma, Medullary; Humans; Hypertension, Renal; Kidney Failure, Chronic; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes | 2002 |
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Topics: Carcinoid Tumor; Humans; Middle Aged; Neuroendocrine Tumors; Octreotide; Pain, Intractable; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes | 2002 |
New advances in peptide receptor radionuclide therapy.
Topics: Humans; Kidney; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Yttrium Radioisotopes | 2002 |
Kidney failure after treatment with 90Y-DOTATOC.
Topics: Aged; Carcinoid Tumor; Female; Humans; Intestinal Neoplasms; Kidney Failure, Chronic; Octreotide; Radiation Injuries; Yttrium Radioisotopes | 2002 |
90Y-DOTATOC and nephrotoxicity.
Topics: Animals; Carcinoid Tumor; Humans; Intestinal Neoplasms; Kidney; Kidney Failure, Chronic; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2002 |
Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Topics: Adult; Aged; Carcinoma, Medullary; Female; Humans; Male; Middle Aged; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Retrospective Studies; Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes | 2004 |
Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma. A Case Report.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Merkel Cell; Cheek; Facial Neoplasms; Fatal Outcome; Female; Humans; Octreotide; Radiopharmaceuticals; Skin Neoplasms; Yttrium Radioisotopes | 2004 |
A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Topics: Animals; Body Burden; Computer Simulation; Drug Evaluation, Preclinical; Femoral Neoplasms; Indium Radioisotopes; Lutetium; Metabolic Clearance Rate; Models, Biological; Octreotide; Organ Specificity; Radiation Dosage; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Wistar; Relative Biological Effectiveness; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Yttrium Radioisotopes | 2004 |
Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Topics: 3-Iodobenzylguanidine; Drug Therapy, Combination; Humans; Iodine Radioisotopes; Models, Biological; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radiopharmaceuticals; Yttrium Radioisotopes | 2006 |
[Peptide receptor radionuclide therapy of neuroendocrine tumors].
Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Yttrium Radioisotopes | 2009 |
Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Gastrinoma; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Radioisotopes; Receptors, Peptide; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
Topics: Adult; Disease Progression; Female; Humans; Indium Radioisotopes; Intestinal Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Receptors, Peptide; Somatostatin; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
Topics: Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peptides, Cyclic; Radiopharmaceuticals; Receptors, Somatostatin; Retreatment; Somatostatin; Stomach Neoplasms; Yttrium Radioisotopes | 2012 |
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
Topics: Aged; Female; Humans; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2013 |
A five-compartment biokinetic model for
Topics: Adult; Aged; Female; Humans; Kidney; Male; Middle Aged; Models, Biological; Monte Carlo Method; Neuroendocrine Tumors; Octreotide; Radiotherapy Dosage; Yttrium Radioisotopes | 2018 |
The β
Topics: Beta Particles; Humans; Injections; Meningioma; Occupational Exposure; Octreotide; Positron-Emission Tomography; Radiation Dosage; Surgery, Computer-Assisted; Yttrium Radioisotopes | 2019 |
225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation.
Topics: Actinium; Humans; Neuroendocrine Tumors; Octreotide; Receptors, Somatostatin; Yttrium Radioisotopes | 2021 |